Furthermore, when analyzing subgroup treatments, the KEYNOTE-671 trial, which performed a neoadjuvant immunotherapy treatment, described a beneficial association between Pembrolizumab efficacy and the PD-L1 tumor expression. This evidence concerns the gene CD274 and neoplasm.